<DOC>
	<DOCNO>NCT01829763</DOCNO>
	<brief_summary>Spasticity motor disorder characterize velocity-dependent increase tonic stretch reflex exaggerate tendon jerk ( Lance 1980 ) . Patients brain lesion often display spasticity due interruption descend pathway control spinal reflex network , result hyperexcitability monosynaptic reflex trigger stretch muscle spindle . Spasticity low limb muscle impairs gait , especially stroke main cause neurological disability . While 80 % stroke survivor recover ability walk , poor quality gait constitute serious handicap daily life ( Bensoussan et al . 2004 ; Bensoussan et al . 2006 ) . Local injection Botulinum toxin ( BTx ) become mainstay treatment focal spasticity , particularly post-stroke patient . BTx weaken excessive muscle contraction block release acethylcholine motoneuron terminal neuromuscular junction transiently paralyze muscle several month . Besides peripheral action , BTx assume also central effect ( Curra et al . 2004 ; Gracies 2004 ; Krishnan 2005 ; Palomar Mir 2012 ) . In particular , affect also fusimotor synapsis intrafusal muscle fiber ( Rosales Dressler 2010 ; Trompetto et al . 2008 ; Trompetto et al . 2006 ) , BTx may reduce discharge muscle spindle , may indirectly responsible functional change central motor mechanisms spinal supraspinal level . Animal experiment also suggest BTx carry retrograde axonal transport motoneuron soma possibly transynaptically , affect spinal cholinergic synaptic transmission spinal cord . Until , electrophysiological finding limit controversial , probably due various motor disorder investigate , physiological mechanism test different toxin injection protocol use study available ( Frascarelli et al . 2011 ; Girlanda et al . 1997 ; Modugno et al . 1998 ; Naumann Reiners 1997 ; Pauri et al . 2000 ; Priori et al . 1995 ; Wohlfarth et al . 2001 ) . Hence , central action toxin spasticity remain uncertain .</brief_summary>
	<brief_title>Central Effects Botulinum Toxin : Neurophysiological Study Stroke Patients With Spastic Lower Limb</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>More 18yearsold Patient Patient present hemiplegia séquellaire AVC tentoriel date 12 month Patient present spasticité muscle leg Patient ( ) ( ) indication treatment ( process ) botulinal toxin carry ( wear ) Patient receive treatment ( process ) botulinal toxin level lower limb six month Patient benefit alcoholization surgical gesture ( movement ) level lower limb twelve month Spasticité focus muscle leg : soleus , gastrocnémiens , score Ashworth &gt; = 2 concerned muscle and/or presence clonus soleus gastrocnémiens , Patient ( ) ( ) upright posture and/or walking ( step ) impossible Patient present contraindication use botulinal toxin Patient present contraindication use intramuscular way Patient susceptible participate totality study Woman pregnant susceptible pregnant year Patient give ( ) consent ( hold ( detain ) , major guardianship ) Patient incapable understand ( include ) nature purpose study , present difficulty understand compromise good progress study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>